logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5870.produswest2
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5870.produswest2
World Hepatitis Day 2022 | Collections | MSF Science Portal
World Hepatitis Day 2022

World Hepatitis Day 2022

Each year hundreds of millions of people suffer from chronic or acute liver disease caused by hepatitis viruses, and over one million die. To mark World Hepatitis Day (July 28th) we bring you a selection of MSF research exploring how to better prevent, identify and treat hepatitis infection in lower-income countries and emergency contexts where the burden is heaviest.

For example, in a South Sudanese camp for displaced people—a type of setting where poor sanitation and water quality regularly lead to hepatitis E outbreaks—MSF and the Ministry of Health (MoH) are conducting the world’s first reactive vaccination campaign against this disease, and evaluating the process and outcomes.

In Cambodia, MSF and MoH collaborators found that a simplified community-based model of care for hepatitis C was safe and highly effective in diagnosing patients and in curing them with new antiviral drugs. It was also cost-effective, according to studies in several countries and patient populations. And these new drugs were safe and effective even in patients also being treated for drug-resistant tuberculosis.

Collection Content

Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (11)
  • CSV
  • BibTeX
  • EndNote
Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (11)
  • CSV
  • BibTeX
  • EndNote

See more collections

ASTMH Annual Meeting 2024

ASTMH Annual Meeting 2024

The American Society of Tropical Medicine & Hygiene (ASTMH) Annual Meeting is an international forum for the exchange of scientific and clinical advances in tropical medicine, hygiene and global health. The scientific content this year is 53% microbe focused, 15% clinically focused, 13% vector focused, 13% globally focused, and 6% intervention focused.

MSF and Epicentre are presenting on access and other challenges for children with visceral and cutaneous leishmaniasis, hurdles in malaria diagnostic testing, and ensuring equitable access to healthcare in conversations about financial sustainability.

This collection features research authored by the presenters and other topics highlighted at ASTMH.

The endTB project

The endTB project
Combatting antibiotic resistance 2022

Combatting antibiotic resistance 2022
View All Collections

The endTB project aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels

Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners Unitaid and the Transformational Investment Capacity (TIC) of MSF. This collection contains the final and intermediate results of the studies, advocacy reports, and study presentations. For more information about the endTB project, visit https://endtb.org/.

Resistance to antibiotics is a growing public health crisis, especially in countries with fragile health systems and in regions at war. The World Health Organization has estimated that antibiotic-resistant bacteria caused nearly 1.3 million deaths in 2019, a toll that will increase significantly in the coming years if effective action is not taken. To mark World Antimicrobial Awareness Week 2022 (18-24 November) we present a snapshot of MSF’s recent work on responding to this growing threat. Since many humanitarian settings lack laboratory capacity to diagnose these infections, MSF and partners have developed two new technologies with the potential to dramatically expand the availability of accurate diagnosis—allowing clinicians to then tailor antibiotic treatment accordingly. Other work from diverse contexts describes practices and challenges related to optimizing rational antibiotic use within health facilities and communities. Lastly, several studies characterize the patterns and prevalence of antibiotic resistance among MSF patients, from hospitalized neonates in Central African Republic to acute trauma patients in Haiti and Yemen.
Journal Article
|
Letter

The first reactive vaccination campaign against hepatitis E

Ciglenecki I, Rumunu J, Wamala JF, Nkemenang P, Duncker J,  et al.
2022-08-01 • Lancet Infectious Diseases
2022-08-01 • Lancet Infectious Diseases
Conference Material
|
Video

The first reactive mass vaccination campaign against Hepatitis E in Bentiu, South Sudan

Nesbitt RC
2022-06-21 • Epicentre Scientific Day Paris 2022
2022-06-21 • Epicentre Scientific Day Paris 2022
Journal Article
|
Research

Integrating hepatitis C treatment into multidrug-resistant TB care

Kirakosyan O, Melikyan N, Falcao J, Khachatryan N, Atshemyan H,  et al.
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
BACKGROUND
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...
Journal Article
|
Research

Prevention of mother-to-child transmission of hepatitis B virus in antenatal care and maternity services, Mozambique

Loarec A, Nguyen AP, Chissano M, Madeira N, Rusch B,  et al.
2021-12-02 • Bulletin of the World Health Organization
2021-12-02 • Bulletin of the World Health Organization
OBJECTIVE
To pilot an intervention on the prevention of mother-to-child transmission (PMTCT) of hepatitis B virus (HBV) in an antenatal care and maternity unit in Maputo, Mozambique,...
Journal Article
|
Research

Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system

Zhang M, O'Keefe D, Craig J, Samley K, Bunreth V,  et al.
2021-03-19 • Lancet Gastroenterology and Hepatology
2021-03-19 • Lancet Gastroenterology and Hepatology
BACKGROUND
Direct-acting antiviral treatment for hepatitis C virus (HCV) has provided the opportunity for simplified models of care delivered in decentralised settings by non-special...
Journal Article
|
Research

Hepatitis C viraemic and seroprevalence and risk factors for positivity in Northwest Cambodia: a household cross-sectional serosurvey

Lynch E, Falq G, Sun C, Bunchhoeung PDT, Huerga H,  et al.
2021-02-26 • BMC Infectious Diseases
2021-02-26 • BMC Infectious Diseases
BACKGROUND
Despite a dramatic reduction in HCV drug costs and simplified models of care, many countries lack important information on prevalence and risk factors to structure effecti...
Journal Article
|
Research

Concomitant treatment of chronic hepatitis C with direct-acting antivirals and multidrug-resistant tuberculosis is effective and safe

Melikyan N, Huerga H, Atshemyan H, Kirakosyan O, Sargsyants N,  et al.
2021-01-04 • Open Forum Infectious Diseases
2021-01-04 • Open Forum Infectious Diseases
We assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 M...
Journal Article
|
Research

Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan

Mafirakureva N, Lim AG, Khalid GG, Aslam K, Campbell L,  et al.
2020-11-04 • Journal of Viral Hepatitis
2020-11-04 • Journal of Viral Hepatitis
Despite the availability of effective direct-acting antiviral (DAA) treatments for Hepatitis C virus (HCV) infection, many people remain undiagnosed and untreated. We assessed the cost-e...
Journal Article
|
Research

An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis

Mafirakureva N, Stone J, Fraser H, Nzomukunda Y, Maina A,  et al.
2020-06-29 • Society
2020-06-29 • Society
BACKGROUND AND AIMS
Hepatitis C virus (HCV) treatment is essential for eliminating HCV in people who inject drugs (PWID), but has limited coverage in resource-limited settings. We me...
Journal Article
|
Research

Cost and cost-effectiveness of a simplified treatment model with direct-acting antivirals for chronic hepatitis C in Cambodia

Walker JG, Mafirakureva N, Iwamoto M, Campbell L, Kim CS,  et al.
2020-05-31 • Liver International
2020-05-31 • Liver International
BACKGROUND & AIMS
In 2016, Médecins Sans Frontières established the first general population Hepatitis C virus (HCV) screening and treatment site in Cambodia, offering free direct-ac...
Conference Material
|
Poster

Outcomes of hepatitis C treatment in vulnerable populations co-infected with HIV and hepatitis C: Programme description, Manipur, India

Himanshu M, Lin Oo W, Cavalheiro AP, Mesic A, Shougrakpam J,  et al.
2020-05-20 • MSF Scientific Days International 2020
2020-05-20 • MSF Scientific Days International 2020